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Multiple myelomaa b s t r a c t
Immunomodulatory drugs such as thalidomide, lenalidomide, and pomalidomide exhibit high
responsive rates for newly identiﬁed or relapsed multiple myeloma patients. However, their mech-
anisms of action are not completely understood. One mechanism involves the ubiquitination and
degradation of two transcription factors, IKZF1 and IKZF3. Whether there are other degradation
pathways for IKZF1 in myeloma cells remains unknown. Here, we found that although IKZF1 ubiq-
uitination was reduced, its stability was also signiﬁcantly reduced in MM1.S and OPM2 cells treated
with kinase inhibitors, 5,6-dichlorobenzimidazole riboside (DRB) or roscovitine. Through pharma-
cological inhibition and biochemical approaches we demonstrated that instead of undergoing the
ubiquitin–proteasome pathway, IKZF1 was degraded through apoptosis induced by kinase inhibi-
tion. This result may provide a new direction in developing therapeutic treatments for myeloma
patients.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Multiple myeloma is the second most common hematological
malignancy which causes immunodeﬁciency due to problems in
generating normal blood cells in bone marrow [1]. Frontline treat-
ments for this disease include the use of steroids such as dexam-
ethasone, proteasome inhibitors such as bortezomib and
carﬁlzomib, immunomodulatory drugs (IMiDs) such as thalido-
mide, lenalidomide, and pomalidomide, or their combination[2,3]. However, the exact mechanisms of action of these drugs
are not completely understood. Treatment of newly identiﬁed or
relapsed myeloma patients with IMiDs such as lenalidomide and
pomalidomide resulted in high overall responsive rates [4,5],
which promoted the elucidation of the mechanisms of action of
these drugs. Recent studies discovered that thalidomide and its
structural analog lenalidomide exhibited their therapeutic effects
on the death of multiple myeloma cells through their binding to
a substrate receptor, cereblon (CRBN), of a cullin 4-RING E3 ligase
(CRL4) complex, composing of regulator of cullins-1 (ROC1),
cullin-4, damage-speciﬁc DNA-binding protein 1 (DBB1), and
CRBN [6,7]. This binding further promotes the interaction between
CRBN and two zinc ﬁnger transcription factors, IKZF1 (Ikaros) and
IKZF3 (Aiolos). Thus this CRL4-CRBN E3 ligase ubiquitinates IKZF1
and IKZF3 and leads to their degradation in the 26S proteasome.
Degradation of these two transcription factors results in the death
of myeloma cells [6].
Phosphorylation of many proteins promotes their ubiquitina-
tion and subsequent degradation. For example, glycogen synthase
kinase 3 (GSK3) phosphorylates b-catenin [8] and thus enhances
its ubiquitination and proteasomal degradation [9]. Use of protein
kinase inhibitors of GSK3, such as lithium chloride (LiCl), reduces
the ubiquitination and degradation of b-catenin [10]. IKZF1 could
Fig. 1. Kinase inhibitors reduce the protein level of the transcription factor IKZF1.
(A) Effect of DRB and Rosc on the protein level of exogenously expressed IKZF1 in
HEK293T cells. HEK293T cells were transfected with FLAG-IKZF1 and treated with
DMSO, DRB (50 lM), or Rosc (50 lM) for 8 h. Whole cell lysates were immunoblot-
ted with anti-FLAG and anti-GAPDH antibodies. (B) Effect of three kinase inhibitors
on the protein level of IKZF1 in multiple myeloma cells. MM1.S cells were treated
with DMSO (), DRB (50 lM), roscovitine (Rosc, 50 lM), or LiCl (10 mM) for 5 h
followed by treatment with DMSO () or lenalidomide (Len, 10 lM) for 2 h. Cells
were lysed and the whole cell lysates were blotted with a rabbit anti-IKZF1
antibody or an anti-GAPDH antibody (loading control). (C) Dose-dependent effect of
DRB and Rosc on the protein level of IKZF1 in MM1.S cells. Cells were treated with
different concentrations of DRB and Rosc and lysed. The whole cell lysates were
blotted with anti-IKZF1 and anti-GAPDH antibodies. The lenalidomide (Len)
treatment was used as a positive control for the reduction of the protein level of
IKZF1.
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covered that there were several phosphorylated residues on
IKZF1 and three major kinases, casein kinase II (CK2),
cyclin-dependent kinases (CDKs), and GSK3, were responsible for
the phosphorylation of IKZF1 [11]. Hyper-phosphorylation of
IKZF1 induces its degradation through the ubiquitin–proteasome
pathway (UPP) [12] and, accordingly, lack of the dephosphoryla-
tion on IKZF1 by protein phosphatase 1 results in the increased
degradation of IKZF1 [13]. These results suggest that there is a clear
crosstalk between phosphorylation and ubiquitination for the
degradation of IKZF1 through the UPP.
Besides the UPP, there are other possible routes for protein
degradation or for the reduction of cellular protein levels after
translation. One is the lysosome-mediated degradation. In this
pathway, intracellular proteins are ﬁrst uptaken by lysosome
through autophagy [14] and then cleaved by proteases such as
cathepsins in lysosome [15]. Another route is degradation through
the activation of caspases during apoptosis [16]. In this case, a pep-
tide bond at a speciﬁc location of a protein is cleaved by an execu-
tioner caspase, such as caspase 3, 6, or 7 [17]. The resulting protein
fragments after caspase cleavages may be unstable andsubsequently degraded by other proteases, leading to the reduc-
tion of the cellular protein level [18]. Here we examine whether
IKZF1 can undergo different degradation pathways in myeloma
cells.
Using biochemical approaches, we explore the effect of kinase
inhibitors on the ubiquitination and stability of IKZF1 in multiple
myeloma cells. Surprisingly, we ﬁnd that kinase inhibition causes
the signiﬁcantly reduced protein level of IKZF1 in some multiple
myeloma cells. We further explore the possible mechanism for
the reduced protein level of IKZF1 in myeloma cells through phar-
macological inhibition and ﬁnd that kinase inhibition can reduce
the stability of IKZF1 through the induction of apoptosis. This dis-
covery suggests a potential new route for the treatment of multiple
myeloma through the degradation of IKZF1 by activating caspases.
2. Materials and methods
2.1. Materials
Human embryonic kidney (HEK) 293T cells and multiple mye-
loma cell line MM1.S were from American Type Culture
Collection and OPM2 from DSMZ (Leibniz Institute
DSMZ-German Collection of Microorganisms and Cell Cultures).
The antibodies used in this work were from following companies:
IKZF1 from ImmunoWay, ubiquitin from Santa Cruz Biotechnology,
FLAG M2 from Sigma, CRBN (polyclonal) from Novus Biologicals,
PARP1 and caspase 3 from Cell Signaling Technology, LC3 from
Abgent, GAPDH from HuaAn Biotechnology, and secondary anti-
bodies from Beyotime Biotechnology. Strep-CRBN plasmid was
obtained from a previous work [19] and FLAG-IKZF1 plasmid was
a gift kindly provided by Dr. Yingli Wu at Shanghai Jiaotong
University.
Protease inhibitor cocktail tablet was from Roche.
5,6-Dichlorobenzimidazole riboside (DRB), roscovitine (Rosc, also
called seliciclib), chloroquine (CQ), and cycloheximide (CHX) were
from Sigma, lenalidomide (Len) from J&K Chemical, MG132 from
Santa Cruz Biotechnology, LiCl and NH4Cl from Sinopharm
Chemical Reagent Co., the pan-caspase inhibitor z-VAD-fmk from
Beyotime Biotechnology.
2.2. Treatment of HEK293T or multiple myeloma cells with kinase
inhibitors
HEK293T cells were grown in high glucose Dulbecco’s Modiﬁed
Eagle medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Gibco), 100 units/mL penicillin, and 100 lg/mL strepto-
mycin, transfected with a FLAG-IKZF1 plasmid, and treated with
DMSO, DRB (50 lM), or Rosc (50 lM) for the indicated time. Cells
were lysed on ice in a lysis buffer (150 mM NaCl, 50 mM Tris–
HCl pH 7.4, 0.1% SDS, 1% Triton X-100, 1 mM EDTA) containing
freshly prepared protease inhibitor cocktail. Whole cell lysates or
puriﬁed samples were used for immunoblotting analysis.
Multiple myeloma cell lines MM1.S and OPM2 were grown in
RPMI 1640 medium supplemented with 10% FBS, 100 units/mL
penicillin, and 100 lg/mL streptomycin. Cells were treated with
DRB or Rosc at the indicated concentration for the desired time
and whole cell lysates were used for immunoblotting analysis.
2.3. Cycloheximide treatment
MM1.S and OPM2 were treated with DMSO, DRB (50 lM), or
Rosc (50 lM) along with cycloheximide (100 lM) for the indicated
time. Cells were lysed in lysis buffer containing freshly prepared
protease inhibitor cocktail on ice and the whole cell lysates were
used for immunoblotting of endogenous IKZF1 and GAPDH.
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FLAG-IKZF1 plasmid was transfected alone or co-transfected
with Strep-CRBN plasmids to HEK293T cells. Cells were treated
with DMSO, lenalidomide (10 lM), DRB (50 lM), or Rosc (50 lM)
along with DMSO (as a control) or a proteasome inhibitor MG132
(10 lM) for 4 h prior to lysis. The tagged proteins were puriﬁed
according to methods described previously [20]. Brieﬂy, to purify
FLAG-IKZF1, cell lysates were incubated with anti-FLAG M2 beads
overnight at 4 C and the beads were washed with lysis buffer four
times at 4 C. The FLAG-IKZF1 was eluted with FLAG peptides. For
the puriﬁcation of CRBN complex, cell lysates were incubated with
Strep-Tactin agarose beads overnight at 4 C and the beads were
washed extensively, and the protein complex was eluted with
5 mM desthiobiotin. The eluate and whole cell lysates were used
for immunoblotting analysis. The ubiquitination level of
FLAG-IKZF1 was detected with an anti-ubiquitin immunoblotting.
Anti-FLAG, anti-CRBN, and anti-GAPDH antibodies were used to
detect FLAG-IKZF1, Strep-CRBN, and GAPDH in the puriﬁed sam-
ples or in the whole cell lysates.2.5. Inhibition of proteasome, lysosome, and apoptosis
HEK293T, MM1.S, and OPM2 cells were treated with DMSO,
DRB, or Rosc at the indicated concentration after pretreatment
with a proteasome inhibitor MG132 (in DMSO), lysosomal inhibi-
tors chloroquine (CQ) or NH4Cl (in cell culture water), or the
pan-caspase inhibitor z-VAD-fmk (in DMSO), for inhibition of pro-
teasome, lysosome, and apoptosis, respectively. Whole cell lysates
or puriﬁed samples were used for immunoblotting analysis.2.6. Immunoblotting analysis
Protein samples were mixed with a proper amount of 5 sam-
ple loading buffer, heated at 100 C for 5 min, separated with 8%
SDS–PAGE, and transferred to the Immobilon PVDF membrane
(Millipore). Membrane was blocked with 5% non-fat milk and incu-
bated with primary antibodies for 1 h at room temperature or
overnight at 4 C and washed with TBST (Tris Buffered Saline with
0.1% Tween 20, pH 7.4) three times, each for seven minutes. The
membrane was further incubated with the proper secondary anti-
bodies for 1 h at room temperature and washed again with TBST
four times. The signals were visualized by Immobilon Western
chemiluminescent horseradish peroxidase substrate and recorded
with Bio-Rad ChemiDoc gel imaging system.Fig. 2. DRB and Rosc enhance the degradation of IKZF1 in myeloma cells. MM1.S and OPM
(50 lM) for the indicated time. Cells were lysed and the whole cell lysates were blotted2.7. Measurement of cell viability
Multiple myeloma cell lines were cultured and treated with
DMSO, DRB (50 lM), or Rosc (50 lM) for the indicated times.
Cells were stained with trypan blue and live cells were counted
under a microscope. The relative cell viability upon the drug treat-
ment was obtained by normalizing the number of live cells in the
DRB or Rosc-treated samples to that in the DMSO-treated samples
at the corresponding time point. The experiments were repeated
three times and the relative cell viability was averaged.
3. Results
3.1. Kinase inhibitors reduce the protein level of IKZF1
Recent experiments from several independent groups identiﬁed
two zinc ﬁnger transcription factors, IKZF1 and IKZF3, which were
ubiquitinated and degraded by the 26S proteasome in the treat-
ment of multiple myeloma cells [6,21,22] and T lymphocytes [23]
with IMiDs thalidomide, lenalidomide, and pomalidomide.
Biochemical experiments and crystal structure analysis showed
that IMiDs enhance the interaction between CRBN and these two
transcription factors, promoting their ubiquitination and proteaso-
mal degradation. Phosphorylation reduces the stability of IKZF1
and this reduced stability can be reversed by mutating IKZF1 to a
phosphorylation-resistant mutant [13]. Here, we tested whether
kinase inhibition affected the ubiquitination and stability of
IKZF1. To do so, we ﬁrst transfected FLAG-IKZF1 to HEK293T cells,
treated the cells with kinase inhibitors, DRB and Rosc, and then
immunoblotted the whole cell lysates. DRB and Rosc inhibit CK2
[24] and CDKs [25], respectively. Surprisingly, immunoblotting
with an anti-FLAG antibody showed that kinase inhibitors
decreased the protein level of IKZF1 in HEK293T cells (Fig. 1A).
Next, we asked whether the reduction of the protein level of
IKZF1 by kinase inhibitors also occurs in multiple myeloma cells.
We used three kinase inhibitors, DRB, Rosc, and LiCl, to treat two
multiple myeloma cell lines, MM1.S and OPM2, and examined
the protein level of IKZF1 by immunoblotting. LiCl inhibits GSK3
for phosphorylation of its substrates [10], such as b-catenin [9],
tau [26], and IKZF1 [11]. These three inhibitors reduce the activity
of the major kinases responsible for IKZF1 phosphorylation [11].
Our results showed that endogenous IKZF1 was also signiﬁcantly
reduced after treated with each of the three kinase inhibitors for
5 h (Fig. 1B). The protein level of IKZF1 was not further reduced
when cells were treated again with lenalidomide, which alone
reduces the protein level of IKZF1 through the UPP in myeloma2 cells were treated with cycloheximide (100 lM) and DMSO, DRB (50 lM), or Rosc
for endogenous IKZF1. GAPDH was used a loading control.
Fig. 3. DRB and Rosc induced degradation of IKZF1 does not undergo the ubiquitin–proteasome pathway. (A) DRB and Rosc do not promote the interaction between IKZF1 and
cereblon (CRBN). HEK293T cells were transfected with 10 lg of FLAG-IKZF1 and Strep-CRBN plasmids, and treated with DMSO, Len (10 lM), DRB (50 lM), or Rosc (50 lM) for
4 h in the presence of MG132 (10 lM). Strep-CRBN was afﬁnity-puriﬁed by Strep-Tactin agarose beads and the puriﬁed samples were blotted with anti-FLAG and anti-CRBN
antibodies. Cell lysates were blotted with anti-FLAG, anti-CRBN, and anti-GAPDH antibodies to show similar protein levels. (B) DRB and Rosc inhibit the ubiquitination of
IKZF1 in HEK293T cells. HEK293T cells were transfected with 10 lg of a FLAG-IKZF1 plasmid, and treated with DMSO, DRB (50 lM), or Rosc (50 lM) for 4 h in the absence or
presence of MG132 (10 lM). Cells were lysed and FLAG-IKZF1 was immunoprecipitated with FLAG M2 antibodies. Immunoprecipitates were blotted with anti-ubiquitin and
anti-FLAG antibodies. Whole cell lysates were blotted with anti-FLAG and anti-GAPDH antibodies to show similar protein levels. (C) Proteasome inhibition does not
signiﬁcantly slow down the degradation of IKZF1 induced by kinase inhibitors in myeloma cell lines. MM1.S and OPM2 cells were pretreated with MG132 (10 lM) for 3 h and
then treated with DMSO, DRB (50 lM), or Rosc (50 lM) for additional 5 h. Total time for MG132 treatment was 8 h. Whole cell lysates were blotted with IKZF1 and GAPDH.
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parable for 50 lM DRB or 10 lM lenalidomide treated samples.
However, the reduction in protein level is more robust for the sam-
ples treated with DRB and Rosc than for the samples treated with
LiCl. This result indicates that these three kinase inhibitors may
have slightly different mechanisms or different extents in regulat-
ing the protein level of IKZF1. We used DRB and Rosc in our subse-
quent experiments because of their robust effect on the protein
level of IKZF1. Treatment of myeloma cells with different doses
of DRB and Rosc shows that there is a dose-dependent manner in
the reduction of protein level of IKZF1 induced by these two inhi-
bitors (Fig. 1C). At high concentration, DRB and Rosc have compa-
rable or more robust effect on the reduction of IKZF1 protein than
lenalidomide.
We also treated U266 and RPMI8226 myeloma cell lines with
DRB and Rosc for the same period of time. However, we did not
detect signiﬁcant reduction in the protein level of IKZF1 in these
two cell lines under the similar experimental condition although
the relative cell viability is also reduced after long treatment of
kinase inhibitors (Supplementary Fig. 1). This result suggests that
these two cell lines might require higher dose or longer treatmentof kinase inhibitors in order to see the effect of kinase inhibition. It
is also possible that the reduction of the protein level of IKZF1 in
myeloma cells induced by kinase inhibitors may depend on the
upstream signaling molecules that are differentially regulated in
different myeloma cell lines.
3.2. Kinase inhibition enhances the degradation of IKZF1 in myeloma
cells
We next asked whether the reduction of the protein level of
IKZF1 was caused by protein degradation. To do so, we used
cycloheximide to block protein synthesis and examined the pro-
tein level at various time points in the presence or absence of
kinase inhibitors DRB or Rosc. The immunoblotting of the whole
cell lysates clearly showed that DRB and Rosc increased the dis-
appearance of IKZF1 in MM1.S and OPM2 cells (Fig. 2). This
effect is more robust for the Rosc treatment than for the DRB
treatment. In addition, IKZF1 disappears slightly faster in OPM2
than in MM1.S. These data suggest that the reduction of IKZF1
in myeloma cells upon kinase inhibition is mediated through
protein degradation.
Fig. 4. The reduction of the protein level of IKZF1 induced by DRB and Rosc in
myeloma cells is not prevented by lysosome inhibition. (A) and (B) Lysosomal
inhibitor chloroquine (CQ) does not prevent IKZF1 from degradation induced by
DRB and Rosc in (A) MM1.S and (B) OPM2 cells. MM1.S and OPM2 cells were treated
with H2O or lysosome inhibitor CQ (100 lM) for 3 h and then treated with DMSO,
DRB (50 lM), or Rosc (50 lM) for 5 h. The total treatment time for CQ was 8 h.
Whole cell lysates were blotted with anti-IKZF1 and anti-GAPDH antibodies. (C)
MM1.S cells were treated with DMSO, DRB (50 lM), or Rosc (50 lM) for 5 h and
whole cell lysates were blotted with anti-LC3 and anti-GAPDH antibodies.
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undergo the UPP
It has been shown that thalidomide, lenalidomide, and poma-
lidomide enhance the interaction between IKZF1 and CRBN
[7,27]. CRBN is a substrate receptor of CRL4 E3 ligase [19,28,29],
which recruits substrates for their ubiquitination. Therefore, the
enhanced interaction between CRBN and IKZF1 induced by IMiDs
promotes the ubiquitination of IKZF1. To test whether kinase inhi-
bitors used here have a similar mechanism in regulating the stabil-
ity of IKZF1 as lenalidomide has, we ﬁrst examined the effect of
these two drugs on the interaction between IKZF1 and CRBN. We
coexpressed FLAG-IKZF1 with Strep-CRBN in HEK293T cells and
treated the cells with lenalidomide, DRB, and Rosc along with a
proteasome inhibitor MG132. We then used Strep-Tactin agarose
beads to afﬁnity-purify Strep-CRBN and its interacting proteins
and blotted the puriﬁed samples with anti-FLAG and anti-CRBN
antibodies. Immunoblotting results showed that IKZF1 was readily
detected in the pulldown when the cells were treated with
lenalidomide (Fig. 3A). However, we did not detect IKZF1 whenthe samples were treated with DRB and Rosc although the puriﬁed
samples had similar protein level of CRBN and the cell lysates had
similar protein levels of CRBN and IKZF1 (Fig. 3A). These results
demonstrated that kinase inhibitors cause the degradation of
IKZF1 through a mechanism different from that of lenalidomide
in myeloma cells.
It has been reported that IKZF1 can be degraded through the
UPP in the early stage of the apoptosis of hematopoietic cells
induced by chemotherapy drugs or UV treatment [30]. We asked
whether IKZF1 degradation induced by kinase inhibition was also
possibly through the UPP although kinase inhibitors do not pro-
mote the interaction between CRBN and IKZF1. To do so, we ﬁrst
expressed FLAG-IKZF1 in HEK293T cells followed by treatment
with DMSO, DRB, or Rosc along with MG132. Immunoblotting of
cell lysates showed similar protein level of IKZF1 in four samples
(Fig. 3B). Then we immunoprecipitated FLAG-IKZF1 and blotted
the immunoprecipitates with an anti-ubiquitin antibody. As
expected, our results showed that upon addition of MG132, the
ubiquitination level of IKZF1 is signiﬁcantly increased. However,
pretreatment of cells with DRB and Rosc markedly reduces the
ubiquitination level of IKZF1 (Fig. 3B). This reduced ubiquitination
might be induced by the reduction of phosphorylation on IKZF1 by
kinase inhibitors. However, this reduced ubiquitination does not
increase its protein level (Fig. 1). This result showed that IKZF1
was not degraded through the UPP when HEK293T cells were trea-
ted with kinase inhibitors. We further tested whether this result is
also true for myeloma cells. To do so, we treated myeloma cells
ﬁrst with MG132 for 3 h and then with DRB or Rosc for additional
5 h (Note that the total time for MG132 treatment was 8 h). Our
immunoblotting result showed that although two myeloma cell
lines had slightly different IKZF1 expression level after MG132
treatment, the degradation of IKZF1 by DRB or Rosc was not signif-
icantly inhibited by the addition of MG132 (Fig. 3C). Together,
these experiments suggest that the degradation of IKZF1 upon
the treatment of kinase inhibitors may not undergo the UPP and
different mechanism is responsible for its degradation.
3.4. The degradation of IKZF1 induced by kinase inhibition is not
prevented by lysosomal inhibition
Another mechanism for protein degradation is through the
autophagy-lysosomal degradation pathway. To test whether the
degradation of IKZF1 in myeloma cells induced by kinase inhibition
was through the lysosome pathway or not, we used a lysosome
inhibitor, chloroquine, to impair the lysosome activity in MM1.S
and OPM2 cells. The immunoblotting images showed that the
degradation of IKZF1 was not signiﬁcantly altered when cells were
pretreated with chloroquine for 3 h and then with DRB and Rosc
for additional 5 h in both myeloma cell lines (Fig. 4A and B).
Similar result was obtained when OPM2 cells were treated with
another lysosome inhibitor, NH4Cl (Supplementary Fig. 2). We also
examined the expression of an autophagy marker LC3 after MM1.S
cells were treated with DRB and Rosc. The immunoblotting analy-
sis did not detect any change in LC3-I and LC3-II after drug treat-
ment (Fig. 4C), indicating that no autophagy occurs. These
experiments suggested that DRB and Rosc did not induce autop-
hagy and the degradation of IKZF1 might undergo a pathway dis-
tinct from the autophagy-lysosomal degradation.
3.5. Apoptotic inhibition attenuates the degradation of IKZF1 induced
by kinase inhibition
It has been shown that Rosc can induce apoptosis in human
eosinophil [31] and myeloma cells [32]. We sought to test
whether IKZF1 is degraded through this pathway in myeloma
cells treated with DRB and Rosc. We ﬁrst measured the cell
Fig. 5. Inhibition of apoptosis induced by kinase inhibitors stabilizes IKZF1 in multiple myeloma cells. (A) and (B) Relative cell viability upon treatment with (A) 50 lMDRB or
(B) 50 lM Rosc in MM1.S and OPM2 cell lines. Cells after drug treatment were stained with trypan blue and the live cells were counted under a microscope. The cell viability
was calculated by normalizing the viable cell number with that in the DMSO-treated samples. The experiments were carried out in triplicates and the data were averaged. (C)
The degradation of IKZF1 resulted from kinase inhibition was prevented by the inhibition of caspase activity. MM1.S and OPM2 cells were pretreated with DMSO or a pan-
caspase inhibitor, z-VAD-fmk (25 lM), for 2 h, and then treated with DMSO, DRB (50 lM), or Rosc (50 lM) for 5 h. Cell lysates were blotted for IKZF1, poly(ADP-ribose)
polymerase 1 (PARP1), procaspase 3, and GAPDH. * Represents the full-length or cleaved PARP1.
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ing live cells after trypan blue staining showed that the cell via-
bility was signiﬁcantly reduced after MM1.S and OPM2 cells
were treated with DRB or Rosc. This effect is slightly more
robust for Rosc treatment than for DRB treatment at the same
concentration and MM1.S cells are slightly more sensitive to
both kinase inhibitors than OPM2 cells (Fig. 5A and B). To fur-
ther examine whether the degradation of IKZF1 occurs after
apoptosis, we ﬁrst examined the effect of these two kinase inhi-
bitors on the stability of two apoptotic markers, PARP1 and cas-
pase 3. Indeed, after cells were treated with DRB and Rosc,
PARP1 and procaspase 3 were reduced and the cleaved PARP1
was also detected in the immunoblotting (Fig. 5C). We then pre-
treated the cells with a pan-caspase inhibitor z-VAD-fmk fol-
lowed by the treatment of DRB or Rosc and found that the
cleavage of PARP1 and procaspase 3 was inhibited, which indi-
cates the inhibition of apoptosis (Fig. 5C). When we further
examined the protein level of IKZF1, we found that IKZF1 was
degraded upon treatment with kinase inhibitors, similar as the
results shown in Fig. 1. However, the degradation of IKZF1 was
almost completely inhibited when the cells were pretreated with
z-VAD-fmk (Fig. 5C). This result demonstrated that the degrada-
tion of IKZF1 occurs after the induction of apoptosis and inhibi-
tion of apoptosis can stabilize IKZF1 in myeloma cells treated
with kinase inhibitors.4. Discussion
The mechanism by which IMiDs, thalidomide and its structural
analogs lenalidomide and pomalidomide, cause the death of multi-
ple myeloma cells has been gradually uncovered recently. These
drugs bridge the substrate receptor, CRBN, of an E3 ligase with
two transcription factors IKZF1 and IKZF3, and promote their ubiq-
uitination and degradation, leading to the death of myeloma cells
[6]. The degradation of IKZF1 by the UPP has also been discovered
at the early stage of the apoptosis of hematopoietic cells [30].
Phosphorylation of proteins could promote their subsequent ubiq-
uitination and degradation [33,34]. Phosphorylation of IKZF1 on its
PEST sequences induces its degradation through the UPP [12]. This
information promoted us to study the effect of kinase inhibitors on
the ubiquitination and stability of IKZF1 in myeloma cells.
Our experiment showed that although kinase inhibitors cause
the reduction of IKZF1 ubiquitination in HEK293T cells, they do
not increase the protein level of IKZF1 in both HEK293T cells and
two myeloma cell lines. Instead, the protein level of IKZF1 is signif-
icantly reduced after the treatment with kinase inhibitors. The
cycloheximide treatment experiments showed that the reduced
protein level was due to enhanced protein degradation. Through
investigating different protein degradation pathways, we demon-
strated that IKZF1 was degraded in myeloma cells through the
apoptosis induced by kinase inhibitors but not through the UPP
Y. Liu et al. / FEBS Letters 589 (2015) 2233–2240 2239and autophagy-lysosomal degradation pathway. Upon inhibition of
apoptosis by a pretreatment with a pan-caspase inhibitor, we
found that IKZF1 maintained its protein level. These experiments
demonstrated that IKZF1 was a substrate of caspases and sug-
gested the presence of another pathway for the degradation of
IKZF1 in myeloma cells. In fact, previous studies have also found
that kinase inhibitors induce apoptosis in hematological malig-
nancy [35–37] including multiple myeloma [32]. Together, these
results suggested that IKZF1 could be degraded through the UPP
or through caspase cleavages in multiple myeloma cells. The drugs
used to treat myeloma cells determine which degradation path-
ways IKZF1 may undergo. These results also demonstrated that
the degradation of IKZF1 could be the cause or the consequence
of apoptosis under different circumstances. It should be noted that
the reduction of IKZF1 by kinase inhibition in myeloma cells may
be cell-type speciﬁc because in our experiments two myeloma cell
lines showed signiﬁcant reduction in IKZF1 while other two cell
lines did not show noticeable alteration in the protein level of
IKZF1 upon kinase inhibition for a short period of time. It may also
be possible that different cell lines respond to the kinase inhibition
to different extents for the degradation of a speciﬁc protein.
Degradation of IKZF1 and IKZF3 is critical in the treatment of
myeloma patients with IMiDs. As discussed above, protein degra-
dation could occur in distinct pathways, including the UPP, lysoso-
mal degradation pathway, and apoptosis. Meanwhile, these
degradation pathways interplay with each other at the molecular
level and together determine the cell fate between death and sur-
vival [38]. Methods that activate speciﬁc proteases such as cas-
pases or speciﬁc pathways for the degradation of IKZF1 and
IKZF3 are potential ways for the treatment of multiple myeloma,
especially for myeloma patients with low or no CRBN protein level
but with high levels of these two transcription factors.
In fact, the CRBN protein level is signiﬁcantly low in myeloma
cells treated with bortezomib and dexamethasone for a prolonged
period [39] or myeloma cells resistant to lenalidomide [40]. It has
been shown that IKZF1 and IKZF3 have relative high protein levels
in some myeloma cell lines with low CRBN protein level [22]. In
these cases, targeting IKZF1 and IKZF3 for degradation by other
means may be a feasible approach for the treatment of myeloma.
In addition, discovery of new drugs that enhance the interaction
between these transcription factors and other E3 ligases or sub-
units of E3 ligases for the ubiquitination and subsequent degrada-
tion of these transcription factors might be an alternative route for
the treatment of myeloma patients with low or no CRBN expres-
sion. Similar strategy has been developed to degrade a transcrip-
tional coactivator and thus to delay the progression of leukemia
in mice [41].
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